welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
A Randomized, Double-blind, Placebo-controlled Study of SRP-9001 for Duchenne Muscular Dystrophy (DMD)
study id #: NCT03769116
condition: Muscular Dystrophy, Duchenne
status: active, not recruiting
purpose:The purpose of this study is to evaluate the safety and efficacy of exogenous gene transfer in DMD patients by measuring biological and clinical endpoints in three parts: two 48-week randomized, double-blinded, placebo-controlled periods (Part 1 and Part 2), and an open-label follow-up period (Part 3). Patients who are randomized to placebo in Part 1 will have the opportunity for treatment with SRP-9001 in Part 2.
intervention: SRP-9001, Placebo
mechanism of action: Gene therapy to introduce a version of dystrophin
results: https://clinicaltrials.gov/ct2/show/results/NCT03769116
last updated: October 06, 2020
rareRelated
-
Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business UpdateSolid Biosciences Inc. today reported fi...
-
Preliminary Data and Intention to Dose Escalate in IGNITE DMDToday we announced our intention to move...
-
From Flask to Vat: The Challenges of Scaling Up Gene TherapyOver the past two decades, gene therapy ...
-
L-citrulline and Metformin in Duchenne’s Muscular DystrophyThe purpose of the study is to show that...
-
Clinical Management of Duchenne Muscular Dystrophy: The State of the ArtIntroduction: Duchenne muscular dystrop...
-
Emerging Therapies for Duchenne Muscular Dystrophyhttps://www.youtube.com/watch?v=4qtcyz4U...
-
X-linked recessive genetic defectshttps://medlineplus.gov/ency/imagepages/...